Build an FDA-Cleared VR CBT Digital Therapeutic for Pain

1. 1

   Design an evidence-based VR CBT protocol

   The product is a therapeutic, not entertainment: a structured virtual-reality program delivering cognitive behavioral therapy and pain-neuroscience education for chronic pain, designed with clinical experts. EaseVRx proved the category is FDA-clearable. The clinical protocol and its evidence base are the core of the product. Build it as a medical intervention from day one.

2. 2

   Plan the FDA clearance pathway and trials

   A prescription digital therapeutic requires FDA review supported by clinical trial evidence of safety and effectiveness, the path EaseVRx followed. Design the trials and regulatory strategy early, because they define the timeline (years) and the burn (millions). Engage the FDA through pre-submission meetings. The evidence is the asset and the barrier at once.

3. 3

   Solve reimbursement before you scale

   The DTx sector's defining struggle is reimbursement: even FDA-cleared products have fought to get payers to pay, and the failure to solve this has sunk well-funded companies. Build your payer, coding, and channel strategy from the start, not after clearance. Opioid-sparing framing helps because payers and society want alternatives to opioids, but wanting is not paying. Treat reimbursement as the make-or-break problem it is.

4. 4

   Build the VR product and distribution

   You need a polished, accessible VR experience (hardware strategy, comfort, usability for a pain population that skews older) and a distribution model, whether prescribed through clinicians, delivered through payers and employers, or both. Hardware friction is a real adoption barrier. The clinical content and the delivery experience must both be excellent. Plan how the headset actually reaches the patient.

5. 5

   Go in clear-eyed about the sector's risk

   Be honest that digital therapeutics is a hard, humbling sector, and that FDA clearance is necessary but not sufficient, commercial success requires reimbursement and adoption that have eluded strong teams. Fund accordingly and design the business model around the reimbursement reality. The societal need for opioid-sparing pain treatment is genuine and motivating, but the path is long and capital-hungry. Enter with eyes open, not with app-economics assumptions.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.